Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324


Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins.

Goetzl EJ, Yaffe K, Peltz CB, Ledreux A, Gorgens K, Davidson B, Granholm AC, Mustapic M, Kapogiannis D, Tweedie D, Greig NH.

FASEB J. 2020 Jan 8. doi: 10.1096/fj.201902842R. [Epub ahead of print]


Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments.

Jung YJ, Tweedie D, Scerba MT, Greig NH.

Front Cell Dev Biol. 2019 Dec 4;7:313. doi: 10.3389/fcell.2019.00313. eCollection 2019. Review.


(-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury.

Greig NH, Lecca D, Hsueh SC, Nogueras-Ortiz C, Kapogiannis D, Tweedie D, Glotfelty EJ, Becker RE, Chiang YH, Hoffer BJ.

CNS Neurosci Ther. 2019 Dec 11. doi: 10.1111/cns.13274. [Epub ahead of print]


The p53 inactivators pifithrin-μ and pifithrin-α mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy.

Yang LY, Greig NH, Tweedie D, Jung YJ, Chiang YH, Hoffer BJ, Miller JP, Chang KH, Wang JY.

Exp Neurol. 2020 Feb;324:113135. doi: 10.1016/j.expneurol.2019.113135. Epub 2019 Nov 26.


Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patients.

Seeman MV, Becker RE, Greig NH.

Handb Clin Neurol. 2019;167:3-18. doi: 10.1016/B978-0-12-804766-8.00001-7.


Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.

Li Y, Vaughan KL, Tweedie D, Jung J, Kim HK, Choi HI, Kim DS, Mattison JA, Greig NH.

Sci Rep. 2019 Nov 20;9(1):17208. doi: 10.1038/s41598-019-53356-2.


Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.

Li Y, Glotfelty EJ, Namdar I, Tweedie D, Olson L, Hoffer BJ, DiMarchi RD, Pick CG, Greig NH.

Exp Neurol. 2020 Feb;324:113113. doi: 10.1016/j.expneurol.2019.113113. Epub 2019 Nov 12.


A Pilot Study of Exenatide Actions in Alzheimer's Disease.

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D.

Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.


Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Glotfelty EJ, Delgado T, Tovar-Y-Romo LB, Luo Y, Hoffer B, Olson L, Karlsson T, Mattson MP, Harvey B, Tweedie D, Li Y, Greig NH.

ACS Pharmacol Transl Sci. 2019 Apr 12;2(2):66-91. doi: 10.1021/acsptsci.9b00003. Epub 2019 Feb 11.


Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.

Boi L, Pisanu A, Greig NH, Scerba MT, Tweedie D, Mulas G, Fenu S, Carboni E, Spiga S, Carta AR.

Mov Disord. 2019 Dec;34(12):1818-1830. doi: 10.1002/mds.27799. Epub 2019 Jul 23.


(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.

Lecca D, Bader M, Tweedie D, Hoffman AF, Jung YJ, Hsueh SC, Hoffer BJ, Becker RE, Pick CG, Lupica CR, Greig NH.

Neurobiol Dis. 2019 Oct;130:104528. doi: 10.1016/j.nbd.2019.104528. Epub 2019 Jul 8.


(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice.

Hsueh SC, Lecca D, Greig NH, Wang JY, Selman W, Hoffer BJ, Miller JP, Chiang YH.

Cell Transplant. 2019 Sep-Oct;28(9-10):1183-1196. doi: 10.1177/0963689719854693. Epub 2019 Jun 10.


Pomalidomide Reduces Ischemic Brain Injury in Rodents.

Tsai YR, Tweedie D, Navas-Enamorado I, Scerba MT, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, de Cabo R, Greig NH, Chiang YH, Chen KY.

Cell Transplant. 2019 Apr;28(4):439-450. doi: 10.1177/0963689719850078. Epub 2019 May 16.


Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons.

Chen YH, Bae E, Chen H, Yu SJ, Harvey BK, Greig NH, Wang Y.

Neurotox Res. 2019 Aug;36(2):347-356. doi: 10.1007/s12640-019-00050-w. Epub 2019 May 8.


Is insulin resistance the cause of fibromyalgia? A preliminary report.

Pappolla MA, Manchikanti L, Andersen CR, Greig NH, Ahmed F, Fang X, Seffinger MA, Trescot AM.

PLoS One. 2019 May 6;14(5):e0216079. doi: 10.1371/journal.pone.0216079. eCollection 2019. Retraction in: PLoS One. 2019 Dec 2;14(12):e0226174.


Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.

Banks WA, Greig NH.

Future Med Chem. 2019 Mar;11(6):489-493. doi: 10.4155/fmc-2018-0436. Epub 2019 Mar 26. No abstract available.


Can We Prevent Dementia and Not Prevent Neurons from Dying?

Becker RE, Greig NH.

J Alzheimers Dis. 2019;68(2):489-492. doi: 10.3233/JAD-181300.


Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis.

Skolnick SD, Greig NH.

Trends Neurosci. 2019 Mar;42(3):151-163. doi: 10.1016/j.tins.2018.12.005. Epub 2019 Feb 19. Review.


Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.

Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, Rocktäschel P, Croteau DL, Akbari M, Greig NH, Fladby T, Nilsen H, Cader MZ, Mattson MP, Tavernarakis N, Bohr VA.

Nat Neurosci. 2019 Mar;22(3):401-412. doi: 10.1038/s41593-018-0332-9. Epub 2019 Feb 11.


Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta).

Duffy KB, Ray B, Lahiri DK, Tilmont EM, Tinkler GP, Herbert RL, Greig NH, Ingram DK, Ottinger MA, Mattison JA.

J Alzheimers Dis. 2019;68(1):115-126. doi: 10.3233/JAD-180487.


Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6'-Dithiothalidomide on Traumatic Brain Injury.

Batsaikhan B, Wang JY, Scerba MT, Tweedie D, Greig NH, Miller JP, Hoffer BJ, Lin CT, Wang JY.

Int J Mol Sci. 2019 Jan 24;20(3). pii: E502. doi: 10.3390/ijms20030502.


Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.

Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T.

JAMA Neurol. 2019 Apr 1;76(4):420-429. doi: 10.1001/jamaneurol.2018.4304. Erratum in: JAMA Neurol. 2019 Apr 1;76(4):509.


Role of viruses, prions and miRNA in neurodegenerative disorders and dementia.

Sohrab SS, Suhail M, Ali A, Kamal MA, Husen A, Ahmad F, Azhar EI, Greig NH.

Virusdisease. 2018 Dec;29(4):419-433. doi: 10.1007/s13337-018-0492-y. Epub 2018 Sep 29. Review.


Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, Rachmany L, Kim HK, Choi HI, Hoffer BJ, Pick CG, Greig NH, Kim DS.

Neurobiol Dis. 2019 Apr;124:439-453. doi: 10.1016/j.nbd.2018.11.023. Epub 2018 Nov 22.


Pomalidomide Ameliorates H₂O₂-Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects.

Tsai YR, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, Tweedie D, Luo W, Greig NH, Chiang YH, Chen KY.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3252. doi: 10.3390/ijms19103252.


Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y.

Sci Rep. 2018 Sep 12;8(1):13953. doi: 10.1038/s41598-018-31455-w.


Neuroinflammation and ER-stress are key mechanisms of acute bilirubin toxicity and hearing loss in a mouse model.

Schiavon E, Smalley JL, Newton S, Greig NH, Forsythe ID.

PLoS One. 2018 Aug 14;13(8):e0201022. doi: 10.1371/journal.pone.0201022. eCollection 2018.


Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury.

Karnati HK, Garcia JH, Tweedie D, Becker RE, Kapogiannis D, Greig NH.

J Neurotrauma. 2019 Apr 1;36(7):975-987. doi: 10.1089/neu.2018.5898. Epub 2018 Oct 25.


Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y.

Sci Rep. 2018 Jul 16;8(1):10722. doi: 10.1038/s41598-018-28449-z. Erratum in: Sci Rep. 2018 Sep 12;8(1):13953.


Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke.

Turcato F, Kim P, Barnett A, Jin Y, Scerba M, Casey A, Selman W, Greig NH, Luo Y.

Cell Transplant. 2018 Apr;27(4):607-621. doi: 10.1177/0963689718766328. Epub 2018 Jun 5.


Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?

Hölscher C, De Felice FG, Greig NH, Ferreira ST.

Neuropharmacology. 2018 Jul 1;136(Pt B):159. doi: 10.1016/j.neuropharm.2018.05.021. Epub 2018 May 18. No abstract available.


Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats.

Yu YW, Hsueh SC, Lai JH, Chen YH, Kang SJ, Chen KY, Hsieh TH, Hoffer BJ, Li Y, Greig NH, Chiang YH.

Int J Mol Sci. 2018 Apr 11;19(4). pii: E1153. doi: 10.3390/ijms19041153.


The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.

Miya Shaik M, Tamargo IA, Abubakar MB, Kamal MA, Greig NH, Gan SH.

Genes (Basel). 2018 Mar 21;9(4). pii: E174. doi: 10.3390/genes9040174. Review.


Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities.

Luo W, Tweedie D, Beedie SL, Vargesson N, Figg WD, Greig NH, Scerba MT.

Bioorg Med Chem. 2018 May 1;26(8):1547-1559. doi: 10.1016/j.bmc.2018.01.032. Epub 2018 Feb 10.


(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.

Becker RE, Greig NH, Lahiri DK, Bledsoe J, Majercik S, Ballard C, Aarsland D, Schneider LS, Flanagan D, Govindarajan R, Sano M, Ferrucci L, Kapogiannis D.

Curr Alzheimer Res. 2018;15(9):883-891. doi: 10.2174/1567205015666180110120026. Review.


Drug discovery and development: Role of basic biological research.

Mohs RC, Greig NH.

Alzheimers Dement (N Y). 2017 Nov 11;3(4):651-657. doi: 10.1016/j.trci.2017.10.005. eCollection 2017 Nov. Review.


Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?

Becker RE, Kapogiannis D, Greig NH.

Alzheimers Dement. 2018 Apr;14(4):431-443. doi: 10.1016/j.jalz.2017.11.007. Epub 2017 Dec 12. Review.


Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders.

Lahiri DK, Maloney B, Greig NH.

J Biol Chem. 2017 Dec 8;292(49):20353. doi: 10.1074/jbc.L117.000502. No abstract available.


A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.

Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.

Cell Transplant. 2017 Sep;26(9):1560-1571. doi: 10.1177/0963689717721234. Review.


Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives.

Kamal MA, Greig NH.

Curr Alzheimer Res. 2017;14(11):1138-1139. doi: 10.2174/156720501411171006122827. No abstract available.


(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury.

Chang CF, Lai JH, Wu JC, Greig NH, Becker RE, Luo Y, Chen YH, Kang SJ, Chiang YH, Chen KY.

Brain Res. 2017 Dec 15;1677:118-128. doi: 10.1016/j.brainres.2017.09.015. Epub 2017 Sep 27.


Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine.

Hoffer BJ, Pick CG, Hoffer ME, Becker RE, Chiang YH, Greig NH.

J Biomed Sci. 2017 Sep 9;24(1):71. doi: 10.1186/s12929-017-0377-1. Review.


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T.

Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3.


Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases.

Kamal MA, Greig NH.

Curr Pharm Des. 2017;23(11):1571-1574. doi: 10.2174/1381612823999170201155228. No abstract available.


Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration.

Rachmany L, Tweedie D, Rubovitch V, Li Y, Holloway HW, Kim DS, Ratliff WA, Saykally JN, Citron BA, Hoffer BJ, Greig NH, Pick CG.

Sci Rep. 2017 Jun 16;7(1):3735. doi: 10.1038/s41598-017-03792-9.


Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT, Greig NH, Midoux P, Pichon C, Kamal MA.

Curr Alzheimer Res. 2017;14(11):1164-1181. doi: 10.2174/1567205014666170508121031. Review.


A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease.

Alexiou A, Mantzavinos VD, Greig NH, Kamal MA.

Front Aging Neurosci. 2017 Mar 31;9:77. doi: 10.3389/fnagi.2017.00077. eCollection 2017.


Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity.

Lu T, Kim PP, Greig NH, Luo Y.

Neurotox Res. 2017 Aug;32(2):218-230. doi: 10.1007/s12640-017-9723-z. Epub 2017 Mar 24.


Insulin resistance and exendin-4 treatment for multiple system atrophy.

Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG.

Brain. 2017 May 1;140(5):1420-1436. doi: 10.1093/brain/awx044.

Supplemental Content

Loading ...
Support Center